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Abstract: In response to recent publicity regarding the poten-
tial use of deep brain stimulation (DBS) for reducing tic sever-
ity in Tourette’s syndrome (TS), the Tourette Syndrome Asso-
ciation convened a group of TS and DBS experts to develop
recommendations to guide the early use and potential clinical
trials of DBS for TS and other tic disorders. The goals of these
recommendations are to ensure that all surgical candidates are
(1) fully informed about the risks, benefits, and alternative
treatments available; (2) receive a comprehensive evaluation
before surgery to ensure that DBS is clearly the appropriate
clinical treatment choice; and (3) that early clinical experience
will be documented publicly to facilitate rational decision-
making for both clinical care and future clinical trials. © 2006
Movement Disorder Society
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We recommend that surgical candidates undergo a com-
prehensive preoperative assessment by experts in
Tourette’s syndrome (TS) and comorbid psychiatric dis-
orders to ensure that candidates meet rigorous inclusion
and exclusion criteria, that evaluations use standardized
rating scales, and that electrode placement is carefully
documented. We further recommend complete compre-
hensive postoperative assessments, including neurologi-
cal, psychiatric, and neuropsychological evaluations.
When publishing the results of these early efforts, each
investigating site should use the same anatomical no-
menclature, assessment protocols, programming strate-
gies, and outcome instruments so that results can be
compared across sites. These goals require meticulous
screening, outstanding surgical skills, randomization,
suitable control conditions, and uniform data collection.
These recommendations are consistent with those of-
fered previously for evaluating surgical treatments in
Parkinson’s disease and Huntington’s disease.
Deep brain stimulation (DBS) has proven useful for
treatment of several movement disorders, including Par-
kinson’s disease, essential tremor, and dystonia.1–3 It is
currently under investigation for treatment of several
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other conditions including epilepsy,4 obsessive–compul-
sive disorder (OCD),5 and Tourette’s syndrome or
tics.6–10 The substantial publicity regarding the apparent
successful treatment of TS with DBS has increased in-
terest among individuals with TS, their families, and the
clinicians who care for them. As a patient and family
support agency, the Tourette Syndrome Association
(TSA) has an interest in ensuring that people with TS and
tic disorders and their clinicians receive the latest infor-
mation regarding new and potentially helpful treatments,
but also that new and experimental treatments are eval-
uated in rigorous protocols that can provide critical in-
formation on the safety and efficacy of these therapies.
As scientists who care for people with TS, we are well
aware of how frequently early case reports and open case
series have offered initial hope only for subsequent con-
trolled trials to fail to demonstrate efficacy or reveal
significant safety concerns. Given the great potential for
benefit as well as harm, the TSA convened a group of
internationally recognized experts on TS and DBS to
develop recommendations to guide early investigations
and use of DBS in tic disorders.
The assessment of tic severity for the purposes of
conducting investigations of DBS is challenging given
the complexity of the clinical features, the range of
severity, and the waxing and waning course of tic symp-
toms.11 Because of the waxing and waning course, it is
difficult to interpret the outcome of clinical trials that do
not use randomization and suitable comparison condi-
tions or controls. Based on the efficacy of DBS for other
disorders, and early published reports on a small number
of TS patients, we believe that proceeding with investi-
gations of DBS is justified. We recommend that these
studies be pursued with caution to obtain data that will
guide future decisions on the role of DBS in the treat-
ment of TS. Our proposal has the following goals: (1) to
provide defensible inclusion and exclusion criteria; (2) to
recommend valid and reliable outcome measures; (3) to
stress the importance of collecting comparable data
across centers; (4) to advocate on behalf of the TS
community by the establishing accountability standards
that outline the minimum effort necessary to ensure the
safety of those undergoing the procedure now and in the
future. To achieve these goals will require meticulous
screening, outstanding surgical skills, randomization,
suitable control conditions, and uniform data collection
of data. The assessment protocols and patient selection
criteria detailed here are consistent with those offered
previously to evaluate surgical treatments in Parkinson’s
disease12 and Huntington’s disease.13 Below is basic
background information on TS, the implications that the
phenomenology and natural history of TS may have on
the evaluation of DBS, basic inclusion and exclusion
criteria, and recommendations regarding selecting and
documenting neurosurgical targets, perioperative imag-
ing, and assessment of results in this population.
CLINICAL FEATURES AND NATURAL
HISTORY OF TS
The defining symptoms of TS are motor and phonic
(vocal) tics.14 Motor tics are stereotyped repetitive invol-
untary movements that typically involve the face, head,
and upper body. Phonic (vocal) tics are sounds such as
sniffing, grunting, or barking that are associated with
muscle contractions of the oropharynx and diaphragm.
Tic severity is based on the frequency, intensity, and
complexity of movements and sounds and can range
from simple and infrequent to complex, intense, and
nearly continuous. Tics may also change their anatomical
location, pattern, severity, and complexity over time.
Tics are influenced by environmental factors: stressful
and exciting activities are associated with transient in-
creases in tic severity, and relaxation and calm, focused
activities are associated with transient reduction of tic
severity. Also, like many other medical conditions, psy-
chological factors may affect the symptom expression or
clinical presentation. For example, in extreme cases such
as the ones who might be considered for surgery, there
are reports of patients who exaggerate existing symp-
toms or generate factitious tic-like symptoms.15–17
Tics most often begin in the first decade of life, usually
between 5 and 7 years of age. They wax and wane, with
peak severity in early adolescence with a gradual de-
crease in severity into adulthood.18,19 Remission of tics
may occur in the third decade of life in up to 50% of
patients, but to date, there are no prognostic features that
predict which patients will have a remission in their
symptoms. However, a small percentage of patients have
severe, disabling tics refractory to standard medical treat-
ment that continue or even increase in adulthood.
IMPACT OF THE CLINICAL FEATURES AND
NATURAL HISTORY OF TS ON DBS
TREATMENT
Given the fluid characteristics of tics over time and the
role of environmental and psychological factors in atten-
uating or exacerbating tic symptoms, any clinical trial of
DBS for TS must use sound clinical trial methods (e.g.,
adequate baseline observation periods, randomization,
and suitable control conditions). Suitable candidates for
DBS will be adults who have been evaluated compre-
hensively and who have undergone standard medical
therapy for their tic disorder but who continue to expe-
rience severe tics. Those with an overall mild–moderate
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course during childhood and adolescence and a severe
exacerbation in adulthood are outliers18 and may not be
suitable candidates for this experimental procedure.
Those going through significant but transient psychoso-
cial or other stressors are also not good candidates. In our
experience, patients cannot always be relied upon to
report such stressors. Interviews with secondary infor-
mants (i.e., close family members) are important to iden-
tify these potential stressors. Also, given the potential
complexity of TS symptoms, it may be difficult to assess
intraoperatively the appropriate electrode placement re-
sulting in suboptimal outcome. For example intraopera-
tive assessment may be difficult for patients with self-
injurious tics or prominent head and neck tics.
COMORBID SYMPTOMS IN TS
Although tics are the defining symptoms in TS, many
individuals with TS have other symptoms, including
OCB, attention deficit hyperactivity disorder (ADHD),
anxiety, and mood disorders.20 Up to 50% of patients
with TS have OCB. Similarly, up to 50% of people with
TS have ADHD symptoms. Smaller, but significant, per-
centages have anxiety, depression, or other affective
symptoms. Identification of these comorbid symptoms is
critical as they are often more impairing than the tics
themselves. The diversity of these comorbid symptoms,
and their potentially aggravating effects on tic severity
and overall disability, further complicate the planning
and interpretation of treatment trials that focus on inter-
ventions to reduce tic severity. In addition to comorbid
symptoms, some with TS may also have significant psy-
chosocial problems. Psychosocial difficulties may be as-
sociated with significant impairment that needs to be
accounted for in the patients’ preoperative assessment.
IMPLICATION OF COMORBID SYMPTOMS
IN TS ON DBS TREATMENT
It is not known whether DBS for tics will have a
beneficial, neutral, or deleterious effect on comorbid
symptoms. In published case reports, DBS of the medial
thalamus appears to have had a beneficial effect on some
comorbid symptoms10; however, investigators and clini-
cians should be prepared for the possibility of divergent
results. A complete baseline assessment of comorbid
symptoms and psychosocial functioning is required be-
fore DBS surgery. The goals of these assessments are to
ensure that the (1) subjects selected have chronically
severe tics that account for their disability, (2) comorbid
conditions have been adequately treated and do not ac-
count for significant disability, and (3) subjects can un-
dergo the procedure safely and actively participate in
their postoperative care, that is, adhere to treatment
schedules and recommendations and to participate in the
outcome assessment of their symptoms.
INCLUSION/EXCLUSION CRITERIA
The following inclusion and exclusion criteria have
been developed to identify ideal candidates for DBS. It is
likely that, as more reports are published, these criteria
may need to be re-evaluated. At this time, ideal candi-
dates will have severe and impairing tics and have failed
exhaustive medical and behavioral treatment options.
They should have no medical, neurological, or psychiat-
ric conditions that increase the risk of the procedure or
preclude full participation in the procedure, postproce-
dural care, or compromise the accurate assessment of the
outcomes. Candidates must also be fully prepared for the
possibility that the procedure will not work or may have
deleterious effects, and have the personal resiliency and
social support to live with such a negative outcome.
Eligible subjects should have received and failed to
respond to optimal and systematic treatment for their tics
and comorbid conditions before consideration of surgery.
Psychological assessment should be done to determine
suitability as a surgical candidate. Assessment and treat-
ment of psychosocial factors need to be undertaken to
ensure that the candidate can fully participate in his or
her postoperative care and outcome assessment.
Candidates for DBS in TS should be evaluated by a
multidisciplinary team, including a neurologist, a psychi-
atrist, and a doctoral level psychologist or neuropsychol-
ogist with expertise in TS and comorbid conditions. The
team should explore psychopathologies or psychosocial
factors that may be contributing to symptom severity or
overall impairment. There should be a detailed assess-
ment of the treatment history to establish adequacy of
treatment trials as per current treatment standards.11,20–23
The treatment history should include attempts at manag-
ing these conditions with behavioral interventions.24,25
The time for surgery is not during periods of acute or
subacute, but self-limited psychosocial stress.
Inclusion Criteria
1. The patient must be at least 25 years old (with rare
potential exceptions). Although this criterion is some-
what arbitrary, the goal is to ensure that included indi-
viduals have a stable degree of severity in adulthood that
predicts a low probability of spontaneous improvement
of tics consistent with the natural course of illness.
2. The patient should have a chronic and severe tic
disorder with severe functional impairment. There
should be a standardized videotape assessment docu-
menting tic severity26,27 and a Yale Global Tic Severity
Scale (YGTSS)28 total tic severity score 35/50 for at
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least 12 months. A YGTSS total tics score threshold of
35 falls in the middle of the “marked” severity
range,29–38 indicating “tics frequent and quite noticeable
in most situations most of the time” and includes patients
with “severe” tics,39–49 indicating “tics associated with a
significant impairment in their primary social role such
that functioning in usual settings was impossible or
placed in serious jeopardy.”18 The threshold was chosen
to ensure that subjects undergoing DBS have marked to
severe tics.
3. The patient must have failed conventional medical
therapy for tics. The patient should have failed treatment
trials (lack of efficacy or severe side effects) of adequate
dose and duration of medication from three different
pharmacological classes. Specifically, this medication
should include an alpha-adrenergic agonist, two dopa-
mine antagonists (typical and atypical), and a
benzodiazepine.
4. The patient should have been evaluated for the
suitability, and implementation if suitable, of behavioral
interventions to reduce tic severity or the severity of
comorbid symptoms. Although behavioral treatments for
tics are themselves investigational at this time, the rela-
tively low risk and potential for benefit in some patients
may make a trial of such treatment before surgery a
reasonable precursor to DBS treatment.
5. The patient must have received stable and optimized
treatment of comorbid medical, neurological, and psy-
chiatric disorders for the past 6 months.
6. The patient must be actively involved and compliant
with psychological interventions to address ongoing psy-
chosocial problems. These interventions must have been
in place at for least 6 months.
Exclusion Criteria
1. The patient must not have a tic disorder or other
movement disorder problem attributable to another med-
ical, neurological, or psychiatric disorder.
2. The patient must not have severe medical, neuro-
logical, psychiatric, or cognitive disorders that inordi-
nately increase the risk of a failed procedure, surgical
complications, or impede recovery and assessment of
outcome (e.g., severe cardiovascular, pulmonary, or he-
matological disorders, epilepsy, history of head injury,
stroke, neurodegenerative disease, autism, schizophre-
nia, bipolar disorder, recent substance dependence).
3. The patient must not be likely to benefit from
psychological intervention (with an experienced clini-
cian) for tic suppression.
4. The patient must not have significant psychosocial
factors that increase the risk of the procedure, or com-
plicate the recovery period and assessment of outcome.
For example, a history of noncompliance with previous
medical and psychosocial treatments efforts, multiple
failed medication treatments of inadequate dose or dura-
tion, a history of multiple other surgical procedures with
poor outcome, unexplained gaps in the medical history,
or pending lawsuits or other legal action.
5. The patient must not be unwilling to be involved in
ongoing treatment for psychosocial problems or risk
factors.
IDENTIFICATION OF THE APPROPRIATE
ANATOMICAL TARGET
Stereotaxic neurosurgical treatment of any neurologic
or psychiatric condition requires meticulous target selec-
tion. The modern success of lesioning and DBS in the
treatment of Parkinson’s disease has resulted from the
availability of a good animal model, a testable neuronal
circuit model based on a large body of data, and an
adequate understanding of the anatomy and physiology
of basal ganglia circuits underlying Parkinson’s disease.
Unfortunately, there is no good animal model of TS, the
underlying neuronal circuitry is not well understood, and
the physiology is not known. There is a large body of
data suggesting abnormal basal ganglia function in TS,
but little consensus on which parts of the basal ganglia or
their extensive connections with cerebral cortex are re-
sponsible for tics.29–33,50 Similarly, there is little specific
information on the neuronal circuitry responsible for
comorbid symptoms commonly associated with TS. The
medical literature contains several reports of stereotaxic
lesions for treatment of tics with scant outcome data and
questionable target localization in many cases.9 There
have been a few reports of DBS for TS.6,8,9 The centro-
median–parafascicular complex (CM-PF) of the thala-
mus has been targeted bilaterally in the majority of those
cases,8,10 but the internal segment of the globus pallidus
(GPi),6,8 and the anterior limb of the internal capsule7
have also been targeted. To date, 6 cases of DBS for TS
have been published (Table 1). All have involved bilat-
eral implantation and stimulation. At this time, there are
insufficient data to recommend one site over the others.
It is essential that any investigation of DBS for TS
include accurate postoperative imaging to identify the
actual electrode placement. Even in the hands of expe-
rienced surgeons, there can be a difference of several
critical millimeters between the intended target and the
final electrode placement. In a region such as the medial
thalamus that encompasses many small nuclei, the local-
ization is especially important. It is also important in
GPi, a large structure that includes multiple circuits with
different functions.34 Final target location cannot be as-
sumed from preoperative imaging. Postoperative imag-
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ing is essential. This imaging should be optimized to
allow visualization of the target structure while minimiz-
ing the artifact associated with the DBS lead to allow one
to determine the location of the lead within the target
structure.
Neuroimaging Recommendations
It is necessary to identify accurately the electrode lead
location(s) achieved to evaluate outcomes from DBS and
to facilitate pooling of anatomical data across institu-
tions.35 To this end, it is recommended that a standard-
ized neuroimaging mapping be used pre- and postoper-
atively with equal effort placed on establishing an
“optimal” therapeutic DBS electrode configuration.
The preoperative imaging should be conducted with
magnetic resonance imaging (MRI), and should consist
of multisequence acquisitions permitting analysis with
established morphometric approaches.36 The collection
of high-resolution, three-dimensional (3-D) T1-
weighted, 2-D proton density-weighted, and 2-D T2-
weighted images preoperatively should be accomplished
according to standards recommended by the Interna-
tional Consortium for Human Brain mapping. As an
example, on a GE 1.5T Signa series MR scanner an axial
3-D RF-spoiled gradient echo sequence includes: IR
prep; TE  5 msec; TI  300 msec; flip angle  20
degrees; 16 kHz bandwidth; 256  160 matrix; 1 exci-
tation; field-of-view, 38 cm; and 1.5 mm slice thickness.
This sequence can be acquired in less than 6 minutes and
has the advantage that TS patients with active facial tics
can be imaged several times (3 to 5 acquisitions in
succession) to obtain at least one data set without the
intrusion of movement artifacts. Image sets without sig-
nificant motion artifact can be later summed for enhance-
ment of signal-to-noise. In addition, axial fast spin-echo
proton density and T2-weighted images should be ob-
tained. An example pulse sequence for GE Signa 1.5T
scanners includes the following: TE  12 msec and 120
msec; TR  4,000 msec; 8 echo-train-length; 15.6 kHz
bandwidth; 256  160 matrix; field-of-view 38 cm, slice
thickness 1.5 mm, using phase-correction and autoshim-
ming options. The preoperative MRI should be normal
without evidence of significant structural lesions.
Postoperative imaging should be performed after al-
lowing sufficient time to eliminate transient postopera-
tive changes. Experience with DBS for other movement
disorders suggests that 1 month is sufficient for this.
Although proton MRI has been performed safely in pa-
tients with the DBS stimulation amplitudes set to zero
(the MR will toggle the stimulator on an off, but no
current will be deposited), precautions must be taken that
the DBS leads are not positioned so as to result in
inductive heating during imaging37 (contact the DBS
manufacturer for further details and recommendations on
postoperative use of MR). Safety precautions require in
addition that all patients be warned of the dangers of
exposure to diathermy devices.
Recent case reports of untoward effects of MRI in
subjects with implanted DBS systems suggests that X-
ray computed tomography (CT), rather than MRI, may
be the most prudent approach to postoperative verifica-
tion of lead placement. A steep axial (Towne’s view, to
avoid unnecessary ocular irradiation) slice orientation
with 1.25- to 1.50-mm-thick contiguous slices should be
obtained to extend from the anterior horns of the lateral
ventricles through the parieto-occipital cerebral cortex.
Dosage technique should be used such that reconstruc-
tions adequately depict electrode contacts without exces-
sive beam-hardening artifact (e.g., 170 KeV, 140 MS







YGTSS Post-op YGTSS Reference
36/Fa 24 mos Anxiety, depression, borderline
personality
GPi 84/100 29/100 (8)
CM-PF 84/100 30/100
27/M 14 mos Depression GPi 83/100 44/100 (6)
42/M 5 yr OCD CM-PF N.R. N.R.; video tic count
decreased 90%
(10)
28/M 1 yr OCD CM-PF N.R. N.R.; video tic count
decreased 72%
(10)
45/M 8 mos Possible OCD CM-PF N.R. N.R.; video tic count
decreased 83%
(10)
37/F 18 mos None AIC N.R. 20% improved (7)
aElectrodes were implanted bilaterally into both GPi and CM-PF in this patient. Stimulation of both GPi and CM-PF did not provide additional
benefit.
DBS, deep brain stimulation; TS, Tourette’s syndrome; AIC, anterior limb of internal capsule; CM-PF, centromedian–parafascicular complex; GPi,
globus pallidus pars interna; N.R., not reported; OCD, obsessive–compulsive disorder; YGTSS, Yale Global Tic Severity Scale.
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technique in a GE Lightspeed scanner). The postopera-
tive CT can be digitally coregistered with the preopera-
tive MRI to improve anatomic localization of the elec-
trode contacts.36,38
POSTOPERATIVE ASSESSMENT
Experience with DBS in Parkinson’s disease and
tremor has shown that there is often a “microlesion”
effect shortly after electrode placement.3,39,40 In dystonia,
it may take several days to weeks for the effect of
stimulation to become apparent.41 Thus, to evaluate DBS
in TS, it is important that the postoperative assessment of
efficacy and side effects be done after any “microlesion”
effect has subsided and after the stimulation settings
have been stable for several weeks. These should be
serial, blinded evaluations. At least 24 hours should
elapse between OFF and ON evaluations, and both pa-
tient and examiner should be blind to whether the stim-
ulation is on or off. Once the typical latent period be-
tween stimulation onset and optimal tic reduction has
been established, the time between ON and OFF testing
may be modified. A comprehensive preoperative assess-
ment should be performed within 1 month of the surgery.
A reasonable schedule for postoperative ON/OFF eval-
uations would be 3, 6, and 12 months after surgery. We
recommend that annual ON/OFF evaluation be per-
formed thereafter to provide information on long-term
effects, It is important to note that, before reaching the
stage at which these evaluations can be scheduled, sev-
eral empiric adjustments to the stimulation parameters
may be necessary to optimize the stimulation results.
Again, there is little experience with this procedure in
TS. Accordingly, we recommend that only centers with
extensive experience programming DBS take on this
responsibility.
Tics should be evaluated with two methods. The
YGTSS is the most commonly used scale and has good
validity and reliability. However, it is subjective and
based on patient (and family) report. Therefore, a blinded
video-based rating should also be performed.26 The po-
tential for sampling error can limit both the YGTSS and
video-based ratings.
There should be careful pre- and postoperative assess-
ment of comorbid symptoms with valid and reliable
instruments. We do not intend to endorse specific instru-
ments but, rather, encourage the use of these tools to
ensure uniformity across centers. For assessment of ob-
sessive–compulsive symptoms, the Yale–Brown Obses-
sive Compulsive Scale symptom checklist and severity
scale should be used.42,43 For evaluation of ADHD symp-
toms, the Conners’ Adult ADHD Rating Scale should be
used.44
Comprehensive neurological and psychiatric examina-
tions should be performed at each visit.
It is essential that a careful neuropsychological eval-
uation be performed. These should be performed before
surgery and again 6 and 12 months after surgery with
stimulators on and again with stimulators off. The po-
tential side effects of DBS of CM-PF thalamus, anterior
GPi, and anterior limb of the internal capsule are not well
defined. Thus, early investigations must carefully ex-
plore for untoward effects under all stimulation
conditions.
The accumulated body of scientific evidence on the
neurocognitive deficits in TS have yielded relatively
consistent findings with respect to intellectual ability and
the presence of specific neuropsychological deficits and
learning disorders.45 Problems in these areas are present
in a significant percentage of patients. The literature to
date has suggested that intellectual ability is normally
distributed in TS. Whether or not individuals with TS
have significant discrepancies between their verbal
and nonverbal abilities remains unclear due to the lack
of longitudinal studies. Cross-sectional studies have
suggested that, with aging, TS patients may develop a
drift between their verbal and performance IQ with
decrement in the performance IQ and relative stability
in the verbal IQ. This change suggests the possibility
of greater nondominant than dominant hemispheric
dysfunction in TS.
The prevalence of learning disabilities in TS appears
to be similar to the base rates reported for the general
population. There is evidence to suggest that the preva-
lence of learning disorders in TS may actually be lower
than the general population when strict diagnostic crite-
ria are applied. When learning disabilities are present in
TS patients, they tend to be specific for difficulties in
mathematics and written language. Specific neuropsy-
chological deficits in TS consistently have been reported
to include visuomotor integration problems, impaired
fine motor skills, and executive dysfunction, although
recent studies have suggested that the presence of ADHD
may more accurately explain executive function (EF)
deficits in TS.
Moreover, the presence of comorbid neuropsychiatric
conditions in TS, notably ADHD and OCD, appear to
increase significantly the likelihood that an individual
with TS will also have intellectual deficits, a learning
disability, or some demonstrable cognitive impairment.
Thus, the role of neuropsychological assessment is to
identify specific cognitive deficits that might be present
in TS and that might be affected by DBS.
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POTENTIAL NEUROPSYCHOLOGICAL TEST
BATTERY FOR USE IN DBS TRIALS
To monitor for potential adverse neuropsychological
effects of DBS, a minimum test battery is recommended,
using tests that are brief, easy to administer, and do not
require a formally trained neuropsychologist (total ad-
ministration time is approximately 45 minutes). These
cognitive tests all have established psychometric proper-
ties; some have alternate forms for repeated testing and
have demonstrated usefulness in TS samples.
Grooved Pegboard
This test is a timed motor speed and dexterity task that
requires pegs to be placed in grooved holes, using each
hand independently. Performance on tasks of fine motor
skill highly dependent on visual perceptual skills, such as
the Grooved Pegboard, appears to be consistently im-
paired in TS patient samples46–48 Administration time is
approximately 5 minutes.
Judgment of Line Orientation
This is a motor-free test of visuospatial organization
that requires the observer to judge the orientation of lines
in space. In a recent study by Sheppard and colleagues49
using a line orientation task, TS subjects were shown to
be right-biased in judging the midpoint of horizontal.
Administration time is approximately 10 minutes.
Trailmaking Test, Forms A and B
This test is a timed, paper and pencil measure of EF
involving numeric (A) and then alternating alphanumeric
(B) sequencing. This visuomotor task requires mental
tracking, sequencing, and set-shifting.51 Across various
measures of EF in TS studies, a consistent finding has
emerged on measures that may rely more heavily on
timed tasks involving visuomotor skill52 such as Trail-
making. Administration time is approximately 5 minutes.
The Hopkins Verbal Learning Test
This test assesses verbal learning and memory by
using a common memory task requiring the participant to
recall a list of words that is repeated multiple times.
Short delay-free recall, long delay-free recall, cued short
and long recall, and intrusion errors can be measured
with this test. Mahone and colleagues51 found that TS
patients demonstrated significantly more intrusion errors
on verbal list learning trials than controls. Administration
time is approximately 15 minutes.
Verbal Fluency (COWALT)
This is a verbal test that measures word production.
The participant is asked to produce as many words as
possible beginning with a given letter (F-A-S) in a lim-
ited period of time, which is 60 seconds per letter.53 In a
study by Brand and associates54 that used a measure of
verbal fluency in children with TS alone and TS plus
ADHD, the TS plus ADHD group performed signifi-
cantly worse on the verbal fluency task. Administration
time is approximately 5 minutes.
SUMMARY
Deep brain stimulation has the potential to be an effective
therapy in a carefully selected subset of adult patients with
TS in which tics are severe and intractable to medical
therapy. However, at this time, there are many unknowns
about the potential application of this therapy. Initial inves-
tigations must use rigorous inclusion and exclusion criteria,
pre- and postoperative assessment using standardized rating
scales by experts in TS and comorbid psychiatric disorders,
careful documentation of electrode location, and compre-
hensive postoperative assessments including neurological,
psychiatric, and neuropsychological evaluations. Each in-
vestigating site should use the same anatomical nomencla-
ture, assessment protocols, and outcome instruments so that
results can be compared across sites. Ideally, DBS will be
performed at centers with expertise in diagnosing and treat-
ing TS in a multidisciplinary manner. Recognizing the need
for a timely exchange and on-going assessment of clinical
experience among those in the field who are exploring the
DBS option with TS patients, the TSA is pursuing currently
an initiative to facilitate the establishment of a database
repository that would be available to the community.
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